Changing concepts in the management of differentiated thyroid cancer

Seminars in Nuclear Medicine

Volumn 35, Issue 4, 2005, Pages 257-265

  Intenzo, Charles M ^a   Jabbour, Serge ^a   Dam, Hung Q ^b   Capuzzi, David M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHRISTIANA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT THYROTROPIN;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL TRIAL; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID CARCINOMA; THYROID HORMONE METABOLISM;

EID: 24344479240     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.05.003     Document Type: Article

References (78)

1. M.J. Schlumberger Papillary and follicular thyroid carcinoma N Engl J Med 338 1998 297 306
2. E.Y. Soh, O.H. Clark Surgical considerations and approach to thyroid cancer Endocrinol Metab Clin North Am 25 1996 115 139
3. El. Mazzaferri, S.M. Jhiang Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer Am J Med 97 1994 418 428
4. N.A. Samaan, P.N. Schultz, R.C. Hickey The results of various modalities of treatment of well differentiated thyroid carcinoma A retrospective review of 1,599 patients J Clin Endocrinol Metab 75 1992 714 720
5. L.J. DeGroot, E.L. Kaplan, M. McCormick Natural history, treatment, and course of papillary thyroid carcinoma J Clin Endocrinol Metab 7 1990 414 424
6. A.M. Sawka, k. Thephamongkhol, M. Brouwers Clinical review 170 A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer J Clin Endocrinol Metab 89 2004 3668 3676
7. J.B. Wong, M.M. Kaplan, K.B. Myer Ablative radioactive iodine therapy for apparently localized thyroid carcinoma A decision analytic perspective Endocrinol Metab Clin North Am 19 1990 741 760
8. I.D. Hay, W.M. McConahey, J.R. Goellner Managing patients with papillary thyroid carcinoma Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000 Trans Am Clin Climatol Assoc 113 2002 241 260
9. R.J. Robbins, M.J. Schlumberger The evolving role of I-131 for the treatment of differentiated thyroid carcinoma J Nucl Med 46 2005 28S 37S
10. A.B. Schneider, B.R. Line, J.M. Goldman Sequential serum thyroglobulin determinations, 131I scans and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer J Clin Endocrinol Metab 53 1981 1199 1206
11. P.W. Ladenson Recombinant thyrotropin vs thyroid hormone withdrawal in evaluating patients with thyroid carcinoma Semin Nucl Med 30 2000 98 116
12. P.W. Ladenson, L. Braverman, E. Mazzaferri Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma N Engl J Med 337 1997 888 896
13. B. Haugin, F. Pacini, C. Reivers A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer J Clin Endocrinol Metab 84 1999 3877 3885
14. R.J. Robbins, R.M. Tuttle, R.N. Sharaf Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma J Clin Endocrinol Metab 86 2001 619 625
15. M. Luster, F. Lippi, B. Jarzab RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma A comprehensive review Endocrine-Related Cancer 12 2005 49 64
16. P. Ladenson, F. Pacini, M. Schlumberger Thyroid remnant ablation; a randomized comparison of thyrotropin alfa and thyroid hormone withdrawal 2004 Presented at 2004 Annual Meeting of the Endocrine Society, New Orleans, LA, June
17. S. Mariotti, G. Barbesino, P. Caturegli Assay of thyroglobulin in serum with thyroglobulin autoantibodies An unobtainable goal? J Clin Endocrinol Metab 80 1995 468 472
18. B. Schaadt, U. Feldt-Rasmussen, B. Rasmusson Assessment of the influence of thyroglobulin (Tg) autoantibodies and other interfering factors on the use of serum Tg as tumor marker in differentiated thyroid carcinoma Thyroid 5 1995 165 170
19. C.A. Spencer, M. Takeuchi, M. Kazarosyan Serum thyroglobulin autoantibodies prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma J Clin Endocrinol Metab 83 1998 1121 1127
20. M. Ozata, S. Suzuki, T. Miyamoto Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer J Clin Endocrinol Metab 79 1994 98 105
21. F. Pacini, R. Lari, Mazzeos Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer Clin Endocrinol 23 1985 405 411
22. H.W. Muller-Gartner, C. Schneider Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer Cancer 61 1988 976 981
23. El. Mazzaferri, R.J. Robbins, C.A. Spencer A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma J Clin Endocrinol Metab 88 2003 1433 1441
24. V. Fatourechi, I.D. Hay Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases Including comments on the role of serum thyroglobulin monitoring in tumor surveillance Semin Nucl Med 30 2000 107 114
25. El. Mazzaferri, R.T. Kloos Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87 2002 1490 1498
26. R.J. Robbins, J.T. Chon, M. Flesiher Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcrnioma? J Clin Endocrinol Metab 87 2002 3242 3247
27. R. Berbano, S. Naddaf, E. Echmendia Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer Endocr Pract 4 1998 11 16
28. Z. Gulzar, S. Jana, I. Young Neck and whole-body scanning with 5 mCi dose of I-123 as diagnostic tracer in patients with well-differentiated thyroid cancer Endocr Pract 7 2001 244 249
29. A.S. Alzahrani, S. Bakheet, M.A. Mandil I-123 isotope as a diagnostic agent in follow-up of patients with differentiated thyroid cancer Comparison with post I-131 therapy whole body scanning J Clin Endocrinol Metab 86 2001 5294 5300
30. L.F. DeGeus-Oei, H.Y. Oe, G. Hennemann Sensitivity of I-123 whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer Eur J Nucl Med Mol Imaging 29 2002 768 774
31. H.M. Park Stunned thyroid after high dose I-131 imaging Clin Nucl Med 17 1992 501 502
32. I.R. McDougall 74 MBq radioiodine I-131 does not prevent uptake of therapeutic doses of I-131 (i.e. it does not cause stunning) in differentiated thyroid cancer Nucl Med Commun 18 1997 505 512
33. J. Nemec, R. Svatopluk, V. Zamrazil Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers J Nucl Med 20 1979 92 97
34. S.I. Sherman, E.T. Tielens, S. Sostre Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma J Clin Endocrinol Metab 78 1994 629 634
35. W.G. Spies, C.H. Wojtowitcz, S.M. Spies Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high dose I-131 therapy Clin Nucl Med 14 1989 793 800
36. M. Schlumberger, F. Mancusi, E. Baudin I-131 therapy for elevated thyrglobulin levels Thyroid 7 1997 273 276
37. J.D. Pineda, T. Lee, K. Ain Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative scan J Clin Endocrinol Metab 80 1995 1488 1492
38. H.M. Park, Y.H. Park, X.H. Zhou Detection of remnant/metastasis without stunning An ongoing dilemma Thyroid 7 1997 277 280
39. F.A. Leger, M. Izembart, F. Dagousset Decreased uptake of therapeutic doses of 131-iodine after 185-MBq 131-iodine diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma Eur J Nucl Med 25 1998 242 246
40. S.J. Mandel, L.K. Shankar, F. Benard Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer Clin Nucl Med 26 2001 6 9
41. S.D. Sarkar, T.P. Kalapparambath, C.J. Palestro Comparison of I-123 and I-131 for whole-body imaging in thyroid cancer J Nucl Med 43 2002 632 634
42. A. Siddiqi, R.R. Foley, K.E. Britton The role of I-123-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to I-131 scanning Avoidance of negative therapeutic uptake due to stunning Clin Enddocrinol 55 2001 515 521
43. P. Postgard, J. Himmelman, U. Lindencrona Stunning of iodide transport by I-131 irradiation in cultured thyroid epithelial cells J Nucl Med 43 2002 828 834
44. Y.H. Hu, P.W. Wang, St Wang Influence of I-131 dose on subsequent ablation in patients with differentiated thyroid carcinoma Discrepancy between the presence of visually apparent stunning and the impairment of successful ablation Nucl Med Commun 25 2004 793 797
45. H.M. Park, O.W. Perkins, J.W. Edmundson Influence of diagnostic radioiodine on the uptake of ablative dose of iodine-131 Thyroid 4 1994 49 54
46. C.H. Kao Stunned thyroid after a diagnostic dose of I-131 for a whole body scan Clin Nucl Med 23 1998 102 104
47. A.J. Coakley Thyroid stunning Eur J Nucl Med 25 1998 203 204
48. M. Luster Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? Eur J Nucl Med Mol Imaging 31 2004 924 925 [Reply to letter to editor]
49. T.E. Hilditch, M.F. Dempsey, A.A. Bolster Self-stunning in thyroid ablation Evidence from comparative studies of diagnostic I-131 and I-123 Eur J Nucl Med 29 2002 783 788
50. H.S. Wu, H.H. Hseu, W.Y. Lin Decreased uptake after fractionated ablative doses of iodine-131 Eur J Nucl Med Mol Imaging 32 2005 167 173
51. R.K. Jeevanram, D.H. Shah, S.M. Sharma Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients Nucl Med Biol 13 1986 277 279
52. R. Dorn, J. Kopp, P. Heidenreich Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer Largest safe dose using risk-adapted approach J Nucl Med 44 2003 451 456
53. O. Sabri, M. Zimny, M. Schreckenberg Does thyroid stunning exist? A model with benign thyroid disease Eur J Nucl Med 27 2000 1591 1597
54. A. Waxman, L. Ramanna, N. Chapman The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: concise communication J Nucl Med 22 1981 861 865
55. M. Karam, A. Giannoukakis, P.J. Feustel Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates Nucl Med Commun 24 2003 489 495
56. L.F. Morris, A.D. Waxman, G.D. Braustein Thyroid stunning Thyroid 13 2003 333 340
57. M. Medvedec Seeking a radiobiological explanation of thyroid stunning Eur J Nucl Med 28 2001 393 394 [Letter to editor]
58. V. Chengazi, R.E. O'Mara Thyroid stunning after I-131 diagnostic whole-body scanning J Nucl Med 42 2001 986 987 [Reply to letter to editor]
59. S.P. Cholewinski, K.S. Yoo, P.S. Klieger Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq I-131 J Nucl Med 41 2000 1198 1202
60. W. Lees, R. Mansberg, J. Roberts The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq I-131 Eur J Nucl Med 29 2002 1421 1427
61. M.T. Bajen, S. Mane, A. Munoz, J.R. Garcia Effect of diagnostic dose of 185 MBq I-131 on post surgical thyroid remnants J Nucl Med 41 2000 2038 2042
62. J.P. Muratet, A. Daver, J.F. Minier Influence of scanning dose of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma J Nucl Med 39 1998 1546 1550
63. H.Q. Dam, S.K. Kim, H.C. Lin I-131 therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning Radiology 232 2004 527 533
64. K. Nakada, S. Katoh, T. Kaji Does stunning impair prognosis of differentiated thyroid cancer? J Nucl Med 43 suppl 2002 328P
65. N. Arlan, S. Ilgan, M. Serdengecti Post-surgical ablation of thyroid remnants with high-dose I-131 in patients with differentiated thyroid carcinoma Nucl Med Commun 22 2001 1021 1027
66. J.D. Lin, P.F. Kao, T.C. Chao The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma Br J Radiol 71 1998 307 313
67. G.M. Venkataraman, M. Yatin, K.B. Ain Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell lin, KAT-50 Thyroid 8 1998 63 69
68. H. Joensuu, A. Ahomen Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose J Nucl Med 28 1987 910 914
69. 18 F)-2-fluoro-2-deoxy-D- glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels J Clin Endocrinol Metab 84 1999 2291 2302
70. B.B. Chin, P. Patel, C. Cohade Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma J Clin Endocrinol Metab 89 2004 91 95
71. B. Schlutter, K.H. Bohuslavizki, W. Beyer Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin levels and negative I-131 scan J Nucl Med 42 2001 71 76
72. W. Wang, S.M. Larson, R.M. Tuttle Resistance of [F-18}-flurodeoxyglucose- avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine Thyroid 11 2001 1169 1175
73. O.H. Clark, T. Hoelting Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans Thyroid 4 1994 501 505
74. I.R. McDougall I-131 treatment of I-131 negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma What is being treated? Thyroid 7 1997 69 72
75. E.L. Mazzaferri Treating high thyroglobulin with radioiodine a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80 1995 1485 1487
76. F. Pacini, F. Lippi, N. Formica Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels J Nucl Med 28 1987 1888 1891
77. M. Schlumberger, F. Mancusi, E. Baudin I-131 therapy for elevated thyroglobulin levels Thryoid 7 1997 273 276
78. US Nuclear Regulating Commission 1997 criteria for release of individuals administered radioactive materials Federal Register 62 1997 4120